Product Description
Capecitabine is used to help treat patients with Dukes' C colon cancer (colon cancer that has spread to lymph nodes in the area close to the colon), after having surgery. This medicine is also used to treat metastatic colorectal cancer (cancer of the colon or rectum that has spread to other parts of the body). (Sourced from: https://www.mayoclinic.org/drugs-supplements/capecitabine-oral-route/side-effects/drg-20062501?p=1)
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bosnia, Brazil, Canada, Chile, China, Cuba, Denmark, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, Kazakhstan, Korea, Mexico, Montenegro, Morocco, Netherlands, Norway, Panama, Peru, Poland, Portugal, Puerto Rico, Russia, Saudi Arabia, Serbia, Singapore, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, Uganda, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 144
Highest Development Phases
Phase 3: Adenocarcinoma|Biliary Tract Cancer|Brain Cancer|Breast Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Nasopharyngeal Cancer|Oncology Solid Tumor Unspecified|Peritoneal Cancer|Squamous Cell Carcinoma
Phase 2: Bladder Cancer|Digestive System Cancer|Esophageal Diseases|Glioma|Intestinal Diseases|Liver Cancer|Meningeal Cancer|Meningeal Carcinomatosis|Muscle Cancer|Pancreatic Cancer|Pseudomyxoma Peritonei|Spinal Cord Cancer|Stomach Diseases|Triple Negative Breast Cancer
Phase 1: Adrenocortical Carcinoma|Basal Cell Carcinoma|Head and Neck Cancer|Healthy Volunteers|Male Breast Cancer|Multiple Sclerosis|Oncology Unspecified|Prostate Cancer|Sarcoma|T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BC200714 | P2 |
Not yet recruiting |
Breast Cancer |
2032-04-30 |
|
| CAAA603D12101 | P2 |
Recruiting |
Breast Cancer |
2031-09-09 |
|
| CAAA603D12101 | P2 |
Unknown Status |
Breast Cancer |
2031-06-30 |
|
| 2023-509814-12-00 | P2 |
Unknown Status |
Colorectal Cancer |
2031-03-31 |